Status In progress
Process STA 2018
ID number 1302

Provisional Schedule

Committee meeting: 3 07 January 2020
Expected publication 19 February 2020

Project Team

Project lead Kate Moore

Email enquiries

Evidence Review Group / Assessment Group Liverpool Reviews and Implementation Group (LRIG)


Companies sponsors AstraZeneca (osimertinib)
Others Department of Health and Social Care
  NHS England
  Welsh Government
Patient carer groups Roy Castle Lung Cancer Foundation
Professional groups Association of Cancer Physicians
  British Thoracic Oncology Group
  British Thoracic Society
  Cancer Research UK
  National Lung Cancer Forum for Nurses
  Royal College of Physicians
  Royal College of Radiologists


Comparator companies AstraZeneca (gefitinib)
  Boehringer Ingelheim (afatinib)
  Roche (erlotinib)
General commentators All Wales Therapeutic and Toxicology Centre
  British National Formulary
  Department of Health, Social Services and Public Safety for Northern Ireland
  Healthcare Improvement Scotland
  Scottish Medicines Consortium
  Welsh Health Specialised Services Committee
Relevant research groups Institute of Cancer Research
  National Cancer Research Institute


Key events during the development of the guidance:

Date Update
19 November 2019 Appeal decision
30 September 2019 Appeal
30 September 2019 Appeal
05 July 2019 - 19 July 2019 Final appraisal document
05 July 2019 There is separate guidance on osimertinib for treating for treating locally advanced or metastatic EGFR T790M mutation-positive non-small-cell lung cancer (TA416). Patient access according to the terms of TA416 is unaffected by the draft final recommendations for osimertinib for untreated EGFR-positive non-small-cell lung cancer (ID1302).
23 May 2019 Committee meeting: 2
12 April 2019 - 09 May 2019 Appraisal consultation
20 March 2019 Committee meeting: 1
09 May 2018 The company who produces osimertinib, AstraZeneca, has requested more time to compile the evidence submission for this technology and as a consequence, this appraisal has been rescheduled. This delay means that this appraisal will be removed from the NICE’s reporting targets for timeliness. In addition, through this request for delay the company accepts that this drug will not be eligible to receive interim CDF funding from the date of marketing authorization.
01 March 2018 Invitation to participate
16 November 2017 - 14 December 2017 Consultation on suggested remit, draft scope and provisional matrix of consultees and commentators
28 September 2017 In progress, In progress

For further information on how we develop guidance, please see our page about NICE technology appraisal guidance